Atlas Trials

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Clinical trial NCT03094052 · COMPLETED

Trial details

NCT number
NCT03094052
Sponsor
University of California, San Francisco
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast CancerBreast AdenocarcinomaStage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7
Start date
2018-10-09
Primary completion
2022-10-31
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.